Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grass-SPIRE in Grass Pollen-Induced Allergic Rhinitis
NCT02795273Phase 3Withdrawn
- Sponsor
- NIOX Group
- Start
- May 2016
- Primary completion
- Oct 2018
- Modality
- Peptides, Peptide-based Cancer Vaccines, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR) and allergic conjunctivitis (AC) comparing Grass-SPIRE with Placebo (2 arms). Primary endpoints: Combined Score of symptoms and allergy medication at 66 weeks and Safety of Grass-SPIRE at 66 weeks. Planned start May 2016; status: withdrawn.
02
Drugs
grass-spire
03
Conditions
allergic rhinitis (AR)allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT02795273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02795273.